Article Details
Retrieved on: 2021-09-27 09:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ASLAN004, a potential first-in-class monoclonal antibody that targets the IL-13 receptor, was shown to be well tolerated across all doses.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here